舒尼替尼和Combretastatin+A4联合用药体外抑制人胃癌SGC7901细胞增殖作用研究.pdfVIP

舒尼替尼与Combretastatin A-4 联合用药体外抑制人胃癌SGC-7901 细 胞增殖作用研究  1 2* 1 1 1 胡曼曼 ，胡国新 ，孙丽蓉 ，周曙华 ，熊建华 (1.温州医学院附属温州市第三临床学院，温州市人民医院药学部，浙江 温 州 325000 ；2.温州医学院药学院药理教研室，浙江 温州 325027) 摘要：目的 对舒尼替尼与Combretastatin A-4(CA-4)联合用药的抗肿瘤活性进行研究。方法 SRB 法测定比较舒尼替尼、 CA-4 及联合用药对人胃癌SGC-7901 细胞增殖抑制作用。PI 染色法、DAPI 染色法及Western blot 法检测舒尼替尼联合应 用CA-4 诱导人胃癌 SGC-7901 细胞凋亡作用。结果 联用舒尼替尼和CA-4 在体外能协同抑制人胃癌 SGC-7901 细胞的 增殖。舒尼替尼联用CA-4 能够诱导SGC-7901 肿瘤细胞凋亡，并且伴随着caspase-3 的激活和PARP 的裂解。结论 舒 尼替尼与CA-4 联合用药在体外能协同诱导人胃癌SGC-7901 肿瘤细胞增殖。 关键词：舒尼替尼；CA -4 ；协同作用；细胞凋亡；抗肿瘤活性 中图分类号：R965.1 ；R917.101 文献标志码：A 文章编号：1007-7693(2013)07-0726-05 Synergistic Anti-tumor ctivity of Sunitinib Combined with Combretastatin A-4 in SGC-7901 Cells by Apoptosis 1 2* 1 1 1 HU Manman , HU Guoxin , SUN Lirong , ZHOU Shuhua , XIONG Jianhua (1.Departmnet of Pharmacy，Wenzhou Third Clinical College and Wenzhou People’s Hospital affiliated With Wenzhou Medical College, Wenzhou 325000, China; 2.Departmnet of Clinical Pharmacy, Wenzhou Medical College, Wenzhou 325027, China) ABSTRACT: OBJECTIVE To study the anti-cancer activity of the combination of CA-4 and sunitinib. METHODS The anti-proliferation activity of CA-4 and sunitinib were analyzed by SRB, apoptosis was detected by PI, DAPI and Western blot analysis. RESULTS The present study indicated that the combination of sunitinib and CA-4 exerted synergistic anti-proliferative effects against human gastric cancer cells SGC-7901 in vitro. The enhanced apoptosis induced by sunitinib plus CA-4 was accompanied by the greater extent of caspases-3 activation and PARP cleavage in SGC-7901 cells. CONCLUSION These findings build the rationale for further clinical development of sunitinib and CA-4 against gastric cancer (SGC-7901). KEY WORDS: sunitinib; CA-4; synergy; apo